Insulin Efsitora Alfa + Insulin Degludec
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Type 1 Diabetes
Conditions
Type 1 Diabetes, Diabetes
Trial Timeline
Aug 12, 2022 โ May 7, 2024
NCT ID
NCT05463744About Insulin Efsitora Alfa + Insulin Degludec
Insulin Efsitora Alfa + Insulin Degludec is a phase 3 stage product being developed by Eli Lilly for Type 1 Diabetes. The current trial status is completed. This product is registered under clinical trial identifier NCT05463744. Target conditions include Type 1 Diabetes, Diabetes.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05463744 | Phase 3 | Completed |
| NCT05362058 | Phase 3 | Completed |
| NCT05275400 | Phase 3 | Completed |
Competing Products
20 competing products in Type 1 Diabetes